Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of blood and bone marrow cells, and an elevated risk of progression to acute myeloid leukemia (AML). Patients with higher-risk MDS have a poore...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.24.182 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839635904112623616 |
|---|---|
| author | Stefani Parmentier |
| author_facet | Stefani Parmentier |
| author_sort | Stefani Parmentier |
| collection | DOAJ |
| description | Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of blood and bone marrow cells, and an elevated risk of progression to acute myeloid leukemia (AML). Patients with higher-risk MDS have a poorer prognosis, with up to 40% of them experiencing disease progression to AML within two years of diagnosis. Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative treatment for high-risk MDS. However, its use is limited by factors, such as patient age, comorbidities, cytogenetic profile, performance status, patient preference and donor availability. This article provides an overview of the therapeutic options for higher-risk MDS that are already established or in development, including hypomethylating agents, IDH1/IDH2 inhibitors, BCL2 inhibitors, RARA agonists, selective inhibitors of nuclear export, liposomal dual-drug chemotherapy and agents targeting aberrant inflammation. This review does not give detailed recommendations for single treatments.
PEER REVIEWERED ARTICLE
Peer reviewers:
Prof. Ulrich Germing, Clinic for Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany
One anonymous peer reviewer
This article was received on May 10, 2025; accepted after peer review on May 30, 2025; published online on June 02, 2025. |
| format | Article |
| id | doaj-art-35a0b2a8156b4702bc5762d39a2d7603 |
| institution | Matheson Library |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-35a0b2a8156b4702bc5762d39a2d76032025-07-08T13:28:38ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062025-06-01242Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging TherapiesStefani ParmentierMyelodysplastic syndromes/myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of blood and bone marrow cells, and an elevated risk of progression to acute myeloid leukemia (AML). Patients with higher-risk MDS have a poorer prognosis, with up to 40% of them experiencing disease progression to AML within two years of diagnosis. Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative treatment for high-risk MDS. However, its use is limited by factors, such as patient age, comorbidities, cytogenetic profile, performance status, patient preference and donor availability. This article provides an overview of the therapeutic options for higher-risk MDS that are already established or in development, including hypomethylating agents, IDH1/IDH2 inhibitors, BCL2 inhibitors, RARA agonists, selective inhibitors of nuclear export, liposomal dual-drug chemotherapy and agents targeting aberrant inflammation. This review does not give detailed recommendations for single treatments. PEER REVIEWERED ARTICLE Peer reviewers: Prof. Ulrich Germing, Clinic for Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany One anonymous peer reviewer This article was received on May 10, 2025; accepted after peer review on May 30, 2025; published online on June 02, 2025.https://doi.org/10.36000/HBT.OH.2025.24.182 |
| spellingShingle | Stefani Parmentier Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies healthbook TIMES. Oncology Hematology |
| title | Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies |
| title_full | Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies |
| title_fullStr | Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies |
| title_full_unstemmed | Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies |
| title_short | Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies |
| title_sort | advances in the treatment of higher risk mds current strategies and emerging therapies |
| url | https://doi.org/10.36000/HBT.OH.2025.24.182 |
| work_keys_str_mv | AT stefaniparmentier advancesinthetreatmentofhigherriskmdscurrentstrategiesandemergingtherapies |